Abstract
The epidermal growth factor receptor (EGFR) is a membrane-anchored, 170 kDa, protein tyrosine kinase that has been implicated in tumorigenesis. Recent sequence data from the publicly funded Human Genome Project has led to a revision in the structure of the EGFR gene, as well as an improved understanding of its mutations in tumor cells. The exons and introns of the EGFR gene are contained within 168 kilobases of DNA, including a completely sequenced 123-kilobase first intron. The EGFR gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion (DM) and tandem duplication (TDM) mutants. The most common mutant is EGFRvIII, which arises from recombination between introns 1 and 7 with deletion of intervening sequences. Some human gliomas express 185 kDa and 190 kDa EGFR tandem duplication mutants with constitutive functional activity. These tumors contain EGFR genes with an in-frame tandem duplication of exons 18 through 25 or exons 18 through 26 respectively. Th e TDM also arise from recombination between flanking introns 17 and either 25 or 26. DM and TDM have been found in the same tumors, suggesting that the mechanisms responsible for both types of mutants may be closely related. Each of the introns involved in tumor-specific recombination contain sequences with homology to the recombination signal sequence (RSS) heptamers present in the V(D)J region of the immunoglobulin and T lymphocyte antigen receptor genes. These observations suggest a possible mechanism for oncogenic EGFR gene recombination in malignant gliomas.
Current Genomics
Title: Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Volume: 4 Issue: 1
Author(s): Michael J. Ciesielski and Robert A. Fenstermaker
Affiliation:
Abstract: The epidermal growth factor receptor (EGFR) is a membrane-anchored, 170 kDa, protein tyrosine kinase that has been implicated in tumorigenesis. Recent sequence data from the publicly funded Human Genome Project has led to a revision in the structure of the EGFR gene, as well as an improved understanding of its mutations in tumor cells. The exons and introns of the EGFR gene are contained within 168 kilobases of DNA, including a completely sequenced 123-kilobase first intron. The EGFR gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion (DM) and tandem duplication (TDM) mutants. The most common mutant is EGFRvIII, which arises from recombination between introns 1 and 7 with deletion of intervening sequences. Some human gliomas express 185 kDa and 190 kDa EGFR tandem duplication mutants with constitutive functional activity. These tumors contain EGFR genes with an in-frame tandem duplication of exons 18 through 25 or exons 18 through 26 respectively. Th e TDM also arise from recombination between flanking introns 17 and either 25 or 26. DM and TDM have been found in the same tumors, suggesting that the mechanisms responsible for both types of mutants may be closely related. Each of the introns involved in tumor-specific recombination contain sequences with homology to the recombination signal sequence (RSS) heptamers present in the V(D)J region of the immunoglobulin and T lymphocyte antigen receptor genes. These observations suggest a possible mechanism for oncogenic EGFR gene recombination in malignant gliomas.
Export Options
About this article
Cite this article as:
Ciesielski J. Michael and Fenstermaker A. Robert, Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas, Current Genomics 2003; 4 (1) . https://dx.doi.org/10.2174/1389202033350092
DOI https://dx.doi.org/10.2174/1389202033350092 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactives in Disease Prevention and Health Promotion: Exploiting Combinatorial Effects
Current Bioactive Compounds Current Targeting Strategies for Adenovirus Vectors in Cancer Gene Therapy
Current Cancer Drug Targets <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Current Signal Transduction Therapy A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Steroidal Oximes: Useful Compounds with Antitumor Activities
Current Medicinal Chemistry Therapeutics and Research Related to Glioblastoma: Advancements and Future Targets
Current Drug Metabolism Ginsenoside Rh2 Inhibits Migration of Lung Cancer Cells under Hypoxia via mir-491
Anti-Cancer Agents in Medicinal Chemistry Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Current Medicinal Chemistry Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Automated Brain Tumour Detection and Classification using Deep Features and Bayesian Optimised Classifiers
Current Medical Imaging The Arrestin Fold: Variations on a Theme
Current Genomics Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme
Current Drug Metabolism Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry